Eugia Pharma receives USFDA Approval for Pazopanib Tablets, 200 mg

Aurobindo Pharma Limited's wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. The product is expected to be launched in Q4FY25. The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA.

This is the 179th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Pazopanib Tablets, 200 mg is indicated for the treatment of adults with Advanced Renal Cell Carcinoma (RCC), and Advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1243.70 as compared to the previous close of Rs. 1258.05. The total number of shares traded during the day was 12593 in over 1471 trades.

The stock hit an intraday high of Rs. 1265.95 and intraday low of 1234.60. The net turnover during the day was Rs. 15692800.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EugiaPharmaSpecialities FinalApproval USFDA PazopanibTablets 200mg